Lilly and Almirall's lebrikizumab impresses a year in to eczema trial

Spanish dermatology specialist Almirall (BME: ALM) announced top-line results from one-year analyses of the efficacy and safety of lebrikizumab, an investigational interleukin (IL)-13 inhibitor for the treatment of patients with moderate-to-severe atopic dermatitis (AD) from Eli Lilly (NYSE: LLY).

"Lebrikizumab has proven over a year its potential to be a leading option for the treatment of AD"The new findings from the Phase III trials, ADvocate 1 and 2, showed that eight out of 10 patients who achieved clinical response with lebrikizumab monotherapy at 16 weeks maintained skin clearance at one year of treatment with the once every two weeks or four weeks regimen.

Patients treated with lebrikizumab also maintained itch relief across the two trials over the one-year period. These results build upon positive data from the 16-week, double-blind, placebo-controlled part of the ADvocate program.